FDA Staying The Course Under Ostroff; Hamburg’s Concerns Will Remain Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.
You may also be interested in...
Like Sands Through The Hourglass, So Are Janet Woodcock’s Days As Acting FDA Commissioner
Janet Woodcock has been a no-nonsense acting commissioner, but there’s plenty of drama in the nomination process as opposition and support for her to become permanent head of the US FDA continues to mount while the wait for President Biden’s nominee drags on.
Like Sands Through The Hourglass, So Are The Days Of Woodcock’s Acting FDA Commissionership
Janet Woodcock has been a no-nonsense acting commissioner, but there’s plenty of drama in the nomination process as opposition and support for her to become permanent head of the US FDA continues to mount while the wait for President Biden’s nominee drags on.
Like Sands Through The Hourglass, So Are The Days Of Woodcock’s Acting FDA Commissionership
Janet Woodcock has been a no-nonsense acting commissioner, but there’s plenty of drama in the nomination process as opposition and support for her to become permanent head of the US FDA continues to mount while the wait for President Biden’s nominee drags on.